SCHEMBL1521387

SCHEMBL1521387

CNc1cc2c(cn1)CN(c1cc(N)c(F)cc1C)C(=O)N2C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 7/20 0.39
FGFR3 P22607 4/20 0.39
FGFR4 P22455 3/20 0.39
FGFR2 P21802 3/20 0.39
TNK2 Q07912 7/20 0.35
MAP4K2 Q12851 7/20 0.35
BMX P51813 4/20 0.35
ABL1 P00519 4/20 0.35
KDR P35968 3/20 0.35
PDGFRB P09619 2/20 0.35
KIT P10721 2/20 0.35
LCK P06239 1/20 0.35
FES P07332 1/20 0.35
RET P07949 1/20 0.35
SRC P12931 1/20 0.35
PDGFRA P16234 1/20 0.35
FLT1 P17948 1/20 0.35
EPHA3 P29320 1/20 0.35
EPHB4 P54760 1/20 0.35
TEK Q02763 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1521527 0.88 NNMT (0.38) FGFR1FGFR3FGFR4FGFR2KDR
SCHEMBL1521476 0.86 FGFR4 (0.41) FGFR1FGFR3FGFR4FGFR2
SCHEMBL1521414 0.86 FGFR4 (0.41) FGFR1FGFR4FGFR2NNMT
SCHEMBL1521884 0.84 FGFR1 (0.40) FGFR1FGFR3FGFR4FGFR2TNK2
SCHEMBL1521411 0.84 FGFR4 (0.35) FGFR1FGFR3FGFR4FGFR2TNK2
SCHEMBL1521384 0.83 FGFR1 (0.37) FGFR1FGFR3FGFR4FGFR2KDR
SCHEMBL1521625 0.81 ABL1 (0.47) FGFR1FGFR3FGFR4TNK2MAP4K2
SCHEMBL1521647 0.80 RAF1 (0.37) FGFR1FGFR3FGFR4FGFR2TNK2
SCHEMBL1521797 0.79 TNK2 (0.37) FGFR1FGFR3FGFR4FGFR2TNK2
SCHEMBL1521766 0.77 TNK2 (0.42) FGFR1FGFR3TNK2MAP4K2BMX

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 US disclosed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 US disclosed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases BRAF, PRKDC, RAF1 FGFR1 577/4885FGFR3 811/4885FGFR4 1073/4885
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 FGFR1 577/4885FGFR3 811/4885FGFR4 1073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.